Sight Sciences' fair access campaign aims for insured access to heat and expression therapy for meibomian gland dysfunction

Video

Jim Sluck, VP of Marketing for Sight Sciences' TearCare, shares the impetus behind the company's fair access campaign.

Jim Sluck, VP of Marketing for Sight Sciences' TearCare, sat down with Optometry Times during the 2022 American Academy of Optometry meeting held in San Diego to share the impetus behind the company's fair access campaign.

Editor's note: This transcript has been edited for clarity.

Hi, my name is Jim Sluck, I'm Vice President of TearCare through Sight Sciences. I'm here to talk a little bit about our fair access campaign for insured access to heat and expression therapy.

The reality is there a lot of dry eye patients out there, and the vast majority have obstructive MGD [meibomian gland dysfunction]. We also know that only 5% of those patients are getting heat and expression therapy for this obstructive MGD.

The rationale for this low penetration of heat and expression utilization is that right now, this is a cash pay procedure. When if you think about care for dry eye--drugs, plugs, amniotic membranes--they're all covered by insurance in one shape, way or form. The fair access campaign is really driving for heat and expression, in this case through TearCare, to be an insured and reimbursed therapy that dry eye patients have access to.

We were telling this story to a number of ophthalmologists and optometrists across the country, and as we tell this story of access and fair reimbursement, they're so behind this that we couldn't tell the story one-on-one anymore, we had to start to campaign around it.

The first portion of the campaign that you'll see [is] our company folks talking to optometrists and ophthalmologists about why access is important.

The second portion will be peer-to-peer discussions with optometrists and ophthalmologists to their peer groups, talking about why access to care with a fair reimbursement is really important to overall patient care.

And lastly, it'll be patients talking to their payers about why their doctor should be able to use heat and expression to treat their dry eye, and why their doctors should be fairly reimbursed for that.

So that's the impetus behind the fair access campaign. Talk to us more about finding out more about the fair access campaign and TearCare at any point.

Recent Videos
Danica Marrelli, OD, FAAO, at Glaucoma 360 discussing visual field testing for patients with glaucoma
Walline, OD, PhD, FAAO, states that the best way to learn the benefits of artificial intelligence for your practice is to stay on top of continuing education attendance.
Jeffrey Walline, OD, PhD, FAAO, gives an overview of the AAO's 2024 and what to expect in 2025 and beyond.
Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.
EnVision Summit Cochair Cecelia Koetting, OD, FAAO, Dipl ABO, says that attendees should get ready for more discussion-based panels at this year's conference.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
Bonnie An Henderson in an interview for the EnVision Summit
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
© 2025 MJH Life Sciences

All rights reserved.